Medarex acquired Corixa’s ultra-potent toxin technology and certain preclinical antibody development programmes in oncology and other disease indications. In return, Corixa received US$3.5 M of Medarex stock and an additional US$17.5 M payment. Medarex also purchased certain equipments for US$2.5 M.